OUR MISSION

TB Alliance is a not-for-profit organization dedicated to the discovery, development and delivery of better, faster-acting and affordable tuberculosis drugs that are available to those who need them.

TB is a global pandemic

Tuberculosis (TB) is a global disease, found in every country in the world, and is one of the leading infectious causes of death worldwide.

In 2021, 10 million people fell ill from TB and 1.6 million died.

It's an airborne disease that can be spread by coughing or sneezing.

TB is responsible for economic devastation and feeds a cycle of poverty and illness that entraps families, communities and even entire countries. Among the most vulnerable are women, children and people living with HIV/AIDS.

The lengthy treatment for TB has led to increased resistance to first-line TB drugs. There are roughly 500K annual cases of drug-resistant TB (DR-TB), and DR-TB is responsible for about 29% of deaths from antimicrobial resistance.

Transforming TB Treatment

Today's TB treatments take too long to cure patients, are too complicated to administer, and can be toxic. Most TB patients are treated with four antibiotics over six months. If not properly administered, the TB bacteria can become resistant to the available medication.

Traditionally, patients with DR-TB have been difficult to treat, requiring up to two years or more of therapy, and as many as 14,000 pills. Even so, roughly half of those treated remained uncured.

TB Alliance developed and received approval for a new treatment for highly drug-resistant TB, the first ever developed by a non-profit organization. This three-drug combination regimen treats highly DR-TB in six months with cure rates of approximately 90%.

How we operate

TB Alliance is a not-for-profit Product Development Partnership (PDP), an organizational model designed to accelerate the development of new technologies to fight public health diseases that lack market incentives. As a PDP, TB Alliance builds partnerships between the public, private, academic and philanthropic sectors to achieve its vision of a world in which no one dies of TB.
The largest TB drug pipeline
Before TB Alliance was established in 2000, there were no new TB drugs in clinical development. Today, TB Alliance manages the largest pipeline of new TB drugs in history and has advanced multiple products to market.

Scaling up new cures
The World Health Organization (WHO) announced that it will amend its DR-TB treatment guidelines, allowing for almost all DR-TB patients to be treated programmatically with regimens containing TB Alliance’s new drug, increasing the target population for these therapies to 500K. TB Alliance is committed to ensuring that all who need these treatments can easily access them.

New TB medicines for children
TB Alliance and partners have introduced improved child-friendly TB medicines. More than one million treatment courses have now been ordered by 123 countries. These quality-assured, affordable treatments come in the correct doses and are improved formulations of proven TB medicines. Dissolvable in water, they are fruit-flavored, making it easier for caregivers to administer and for children to take.

Engaging with communities
TB Alliance leverages innovative scientific, strategic, and community-based initiatives to fight TB. These initiatives include partnerships with people with TB and impacted communities, empowering them with knowledge and skills that accelerate the pace, promise, and capacity of TB research.

Without **new and improved TB treatments**, we cannot defeat this deadly pandemic.

**Our commitment**
TB Alliance can only achieve its mission if new, faster-acting and better TB cures are adopted, available and affordable to those who need them. This commitment—our “AAA Mandate”—is TB Alliance’s pledge to ensure that any new TB treatments developed will be used to help people suffering from TB and accelerate progress against the TB pandemic.

**The promise of new cures**
Our ultimate vision is to have a transformative impact on the disease by introducing ultra-short, simple and affordable TB regimens that can cure virtually all people with TB. The introduction of our new DR-TB treatment regimen is a significant step toward this goal. Achieving this mission and saving countless more lives requires a robust pipeline of new therapies and sustained investment in TB R&D.

The benefits of new TB cures include:
- Shorter, simpler and safer treatment, with improved adherence and fewer side effects, reducing the burden of treatment to health care systems, TB programs and patients
- Ability to treat both drug-sensitive and drug-resistant disease with the same regimen, simplifying and enabling the scale-up of therapy globally
- Affordable treatment for DR-TB, at a fraction of the cost of traditional treatment efforts
- Compatibility with HIV/AIDS medications
- Improved treatment outcomes and patient experience
- Safe and effective TB treatments designed specifically for children
- Lifting TB’s enormous economic burden on health systems, freeing up scarce resources that can help achieve Universal Health Coverage

TB Alliance operates with support from Australia’s Department of Foreign Affairs and Trade, Bill & Melinda Gates Foundation, Cystic Fibrosis Foundation, Foreign, Commonwealth and Development Office (United Kingdom), Germany’s Federal Ministry of Education and Research through KfW, Global Disease Eradication Fund (Korea), Global Health Innovative Technology Fund, Indonesia Health Fund, Irish Aid, Korea International Cooperation Agency, Medical Research Council (United Kingdom), National Institute of Allergy and Infectious Diseases, Republic of Korea’s Ministry of Foreign Affairs, and the United States Agency for International Development.